Description: Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, otorhinolaryngology, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, and sports and aging care supplements. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Home Page: www.nippon-shinyaku.co.jp
14, Nishinosho-Monguchi-cho
Kyoto,
601-8550
Japan
Phone:
81 7 5321 1111
Officers
| Name | Title |
|---|---|
| Mr. Toru Nakai | Pres & Director |
| Mr. Takashi Takaya | GM of Personnel, Gen. Affairs, Risk Mgmt, Compliance & Digital Trans and Director |
| Mr. Shouzou Sano | MD, GM of Sales & Marketing and Director |
| Koji Honma | Gen. Mang. of Personnel Dept. |
| Hirokata Harada | Head of Medical Affairs Division & Corp. Officer |
| Mr. Takanori Edamitsu | GM of Bus. Management & Sustainability and Director |
| Mr. Kazuchika Takagaki | GM of R&D Division & Director |
| Mr. Hitoshi Ishizawa | GM of Functional Food Division & Director |
| Masaya Toda | Head of Licensing & Alliance Division and Corp. Officer |
| Masafumi Taira | Corp. Officer & Head of Clinical Devel. Div. |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 19.0476 |
|---|---|
| Trailing PE: | 15.1522 |
| Price-to-Book MRQ: | 2.531 |
| Price-to-Sales TTM: | 0.0192 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |